(Q40608123)

22 September 2017

title

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (English)

1 reference

22 September 2017

1 reference

Emmanuel S. Antonarakis

7

object named as

Emmanuel S Antonarakis

1 reference

22 September 2017

Benjamin L Maughan

1

1 reference

22 September 2017

Xian C Xhou

2

1 reference

22 September 2017

Daniel L Suzman

3

1 reference

22 September 2017

Rosa Nadal

4

1 reference

22 September 2017

Sunakshi Bassi

5

1 reference

22 September 2017

Michael T Schweizer

6

1 reference

22 September 2017

publication date

26 August 2015

1 reference

22 September 2017

1 reference

22 September 2017

volume

75

1 reference

22 September 2017

issue

15

1 reference

22 September 2017

page(s)

1814-1820

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

Androgen pathway resistance in prostate cancer and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

Regulation of the androgen receptor by post-translational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

Sequencing of agents in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23064

21 January 2018

Identifiers

DOI

10.1002/PROS.23064

1 reference

22 September 2017

1 reference